Dengue fever, a mosquito-borne viral illness, continues to pose a important global health threat, with millions of cases reported annually and recent outbreaks straining healthcare systems worldwide.Following years of research, promising developments are emerging in both prevention and treatment, offering renewed hope in the fight against the disease. Brazil recently approved the world’s first single-dose dengue vaccine, and new research details encouraging results from an oral antiviral drug, mosnodenvir, demonstrating its ability to reduce viral load in patients-though concerns about potential resistance are already surfacing.
A potential turning point in the fight against dengue fever has arrived with the recent approval of the world’s first single-dose vaccine and promising results from a new antiviral treatment. Dengue fever, a mosquito-borne illness, infected over 14 million people globally in 2024, highlighting the urgent need for effective prevention and treatment options.
On November 26, Brazil’s health authorities approved the dengue vaccine developed by the Butantan Institute. Simultaneously, research published in The New England Journal of Medicine (NEJM) detailed the success of an oral antiviral, mosnodenvir, in reducing the viral load of dengue in healthy volunteers intentionally infected with the DENV-3 serotype.
Antiviral Shows Promise in Controlled Study
The NEJM study utilized a controlled human infection model (CHIM), where healthy volunteers received a weakened, genetically stable dengue virus. Researchers then compared the effects of three different doses of mosnodenvir against a placebo, administering the drug for five days followed by a 21-day maintenance period. The primary measure of effectiveness was the area under the curve of viral load between days 1 and 29, measured by quantifying viral RNA.
The results were significant: 60% of participants in the high-dose mosnodenvir group (6 out of 10) showed no signs of infection – meaning no detectable viral load, no seroconversion, and no associated symptoms – compared to 0% in the placebo group. Furthermore, the viral load was substantially reduced (p < 0.001) in the high-dose group versus the placebo group.
Mosnodenvir was generally well-tolerated, with no serious adverse events reported in the small study cohort. Drug concentrations in the bloodstream remained stable during the maintenance period. However, researchers observed a variation in amino acids within the NS4B region of the viral genome in all participants receiving mosnodenvir – but not in the placebo group – suggesting the potential for the virus to develop resistance.
These findings confirm that targeting the NS3-NS4B interaction is a valid approach for developing antiviral drugs against dengue. Mosnodenvir, particularly at higher doses, could potentially serve as a prophylactic treatment in areas where dengue is common or for travelers visiting those regions, offering a complement or alternative to vaccination.
Emerging Resistance Concerns
Despite the encouraging results, recent genomic analyses reveal a potential setback. Dengue virus serotype 2 (DENV-2) strains collected during the 2023-2024 epidemic in the French West Indies, among other locations, exhibit a mutation (NS4B:V91A) associated with a significant decrease in sensitivity to mosnodenvir – over 1000 times less sensitive in laboratory settings.
These drug-resistant strains appear to have emerged multiple times over the past three decades in both DENV-2 and DENV-3, posing a serious challenge to the clinical effectiveness of the antiviral against circulating viruses. The emergence of resistance underscores the need for ongoing monitoring and potential development of alternative therapies.
Challenges to Development and Future Research
Another obstacle emerged in October 2024 when Johnson & Johnson announced the discontinuation of its phase 2 trial evaluating the prevention of dengue in adults naturally exposed to the virus. The company cited a strategic reorganization of its research and development portfolio as the reason for the halt, and stated that no safety concerns were identified.
However, research into dengue treatments continues. Novartis launched a phase 2 trial last year for a compound called EYU688, which also targets a protein involved in viral replication, with results expected in September 2026. The Serum Institute of India is currently conducting a phase 3 trial with a monoclonal antibody.
Despite these hurdles, research into dengue is accelerating and making significant progress. Further investigation into both preventative and therapeutic strategies remains crucial to combatting this widespread and debilitating disease.
